This week in transparency news: March 20 – April 3, 2020

by Staff writer,
Posted on 4/3/2020

Clinical trial transparency in the pharmaceutical industry is continually evolving, and to stay on top of the news, TrialAssure brings a bi-weekly round-up of some of the key stories. Select recent and relevant stories are as follows:

FDA Continues to Support Transparency and Collaboration in Drug Approval Process as the Clinical Data Summary Pilot Concludes – U.S. Food & Drug Administration (FDA)

The FDA’s Clinical Data Summary Pilot Program designed to evaluate transparency has officially concluded, after the agency gathered useful feedback. As the pilot ends, the FDA says it commits to improving collaboration efforts with drug-approving regulatory agencies in other countries and to increasing transparency.

Get the latest news from the FDA

Vivli to launch a portal for sharing data from COVID-19 trials – Vivli

Vivli—a nonprofit that houses an independent global data-sharing and analytics platform—just announced the launch of a COVID-19 portal for sharing completed interventional treatment trial data. The portal aims to share clinical data from COVID-19 trials with the entire data-sharing community.

Read the press release here

EudraCT Public Web Report for March 2020—European Medicines Agency (EMA)

The EMA published its monthly public web report for EudraCT. In March 2020, there were 59,648 clinical trials recorded on the database.

Read the entire report